Cargando…

Dynamic monitoring of serum soluble programmed cell death ligand 1 as a response predictor to chemotherapy in metastatic or recurrent gastrointestinal cancer

BACKGROUND: Biomarkers in serum may have important clinical implications for personalized medicine, including therapeutic guidance, and monitoring of recurrence. The role of programmed cell death ligand 1 (PD-L1) expression as a tumor biomarker remains controversial. In this study, we aimed at deter...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Jin, Qiu, Miao-Zhen, Mei, Ting, Gao, Yuan, Chang, Boyang, Zhang, Yuxin, Wang, Feng-Hua, Li, Su
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798804/ https://www.ncbi.nlm.nih.gov/pubmed/35117603 http://dx.doi.org/10.21037/tcr.2020.03.23

Ejemplares similares

Prognostic Value of Serum Soluble Programmed Death-Ligand 1 and Dynamics During Chemotherapy in Advanced Gastric Cancer Patients
por: Park, Woochan, et al.
Publicado: (2021)

The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma
por: Chang, Boyang, et al.
Publicado: (2018)

High Serum Level of Soluble Programmed Death Ligand 1 is Associated With a Poor Prognosis in Hodgkin Lymphoma
por: Guo, Xiaofang, et al.
Publicado: (2018)

Prognostic implications of soluble programmed death-ligand 1 and its dynamics during chemotherapy in unresectable pancreatic cancer
por: Park, Hyunkyung, et al.
Publicado: (2019)

Elevated serum soluble programmed cell death ligand 1 concentration as a potential marker for poor prognosis in small cell lung cancer patients with chemotherapy
por: Jin, Jianjun, et al.
Publicado: (2018)

Cell adhesion molecules in bladder cancer: soluble serum E-cadherin correlates with predictors of recurrence.
por: Griffiths, T. R., et al.
Publicado: (1996)

Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma
por: Wang, Liang, et al.
Publicado: (2015)

Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score
por: Burtness, Barbara, et al.
Publicado: (2022)

Soluble programmed cell death protein-1 and programmed cell death ligand-1 in sepsis
por: Banerjee, Debasree, et al.
Publicado: (2018)

The predictive role of soluble programmed death ligand 1 in digestive system cancers
por: Ruan, Jian, et al.
Publicado: (2023)

Serum 8-Oxo-dG as a Predictor of Sensitivity and Outcome of Radiotherapy and Chemotherapy of Upper Gastrointestinal Tumours
por: Pour Khavari, Ali, et al.
Publicado: (2018)

Plasma soluble programmed death ligand 1 levels predict clinical response in peripheral T‐cell lymphomas
por: Zhang, Xuhan, et al.
Publicado: (2019)

Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma
por: Gao, Yuan, et al.
Publicado: (2017)

Chemotherapy predictors and a time-dependent chemotherapy effect in metastatic esophageal cancer
por: Midthun, Lauren, et al.
Publicado: (2022)

Increase of Soluble Programmed Cell Death Ligand 1 in Patients with Chronic Hepatitis C
por: Yamagiwa, Satoshi, et al.
Publicado: (2017)

Prognostic and predictive role of soluble programmed death ligand-1 in head and neck cancer
por: Molga-Magusiak, Maria, et al.
Publicado: (2023)

Clinical significance of soluble programmed cell death-1 and soluble programmed cell death-ligand 1 in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy
por: Tominaga, Tetsuro, et al.
Publicado: (2019)

Dynamics of Soluble Programmed Death-Ligand 1 (sPDL1) during Chemotherapy and Its Prognostic Implications in Cancer Patients: Biomarker Development in Immuno-oncology
por: Ha, Hyerim, et al.
Publicado: (2019)

Hyperprogression after anti-programmed cell death ligand-1 therapy in a patient with recurrent metastatic urothelial bladder carcinoma following first-line cisplatin-based chemotherapy: a case report
por: Mao, Shiyu, et al.
Publicado: (2019)

Immune checkpoint molecules soluble program death ligand 1 and galectin‐9 are increased in pregnancy
por: Enninga, Elizabeth Ann L., et al.
Publicado: (2017)

High Soluble Programmed Death-Ligand 1 Predicts Poor Prognosis in Patients with Nasopharyngeal Carcinoma
por: Lu, Tianzhu, et al.
Publicado: (2020)

The Prognostic Value of Circulating Soluble Programmed Death Ligand-1 in Cancers: A Meta-Analysis
por: Huang, Pei, et al.
Publicado: (2021)

Soluble monomeric human programmed cell death-ligand 1 inhibits the functions of activated T cells
por: Liang, Zhaoduan, et al.
Publicado: (2023)

Third-line docetaxel chemotherapy for recurrent and metastatic gastric cancer
por: Lee, Ji Hyun, et al.
Publicado: (2013)

Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma.
por: Franzke, A., et al.
Publicado: (1998)

Programmed death ligand‐1 expression in gastrointestinal cancer: Clinical significance and future challenges
por: Yamashita, Kohei, et al.
Publicado: (2020)

Association between serum soluble CD40 ligand levels and mortality in patients with severe sepsis
por: Lorente, Leonardo, et al.
Publicado: (2011)

Levels of soluble delta-like ligand 1 in the serum and cerebrospinal fluid of tuberculous meningitis patients★
por: Li, Jinghong, et al.
Publicado: (2012)

Associations of serum soluble Fas and Fas ligand (FasL) with outcomes in systemic lupus erythematosus
por: Vincent, Fabien B, et al.
Publicado: (2020)

Clinical significance of progranulin correlated with serum soluble Oxford 40 ligand in primary Sjögren's syndrome
por: Qi, Xuan, et al.
Publicado: (2020)

Serum soluble Fas ligand is a severity and mortality prognostic marker for COVID-19 patients
por: Saleki, Kiarash, et al.
Publicado: (2022)

Opposing Roles for Membrane Bound and Soluble Fas Ligand in Glaucoma-Associated Retinal Ganglion Cell Death
por: Gregory, Meredith S., et al.
Publicado: (2011)

Preoperative imatinib for patients with primary unresectable or metastatic/recurrent gastrointestinal stromal tumor
por: Shen, Chaoyong, et al.
Publicado: (2014)

Downregulation of miR-186 is associated with metastatic recurrence of gastrointestinal stromal tumors
por: Niinuma, Takeshi, et al.
Publicado: (2017)

The Use of Molecular Subtypes for Precision Therapy of Recurrent and Metastatic Gastrointestinal Stromal Tumor
por: Liu, Peng, et al.
Publicado: (2020)

Lack of Association of Plasma Levels of Soluble Programmed Cell Death Protein 1, Programmed Death-Ligand 1, and CTLA-4 With Survival for Stage II to IIIA NSCLC After Complete Resection and Adjuvant Chemotherapy
por: Tanizaki, Junko, et al.
Publicado: (2023)

Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy
por: Ha, Hyerim, et al.
Publicado: (2016)

Serum Metabolic Fingerprints on Bowl-Shaped Submicroreactor Chip for Chemotherapy Monitoring
por: Yin, Xia, et al.
Publicado: (2022)

High post-treatment serum levels of soluble programmed cell death ligand 1 predict early relapse and poor prognosis in extranodal NK/T cell lymphoma patients
por: Wang, Hua, et al.
Publicado: (2016)

Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma
por: Cho, Inju, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_le24v9tpsb2sh5c319dk6je5lr